Published in Am J Cardiol on February 06, 2003
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
Pathophysiology of sleep apnea. Physiol Rev (2010) 4.69
S-nitrosylation in cardiovascular signaling. Circ Res (2010) 3.02
Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study. Am J Epidemiol (2008) 2.86
Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol (2010) 1.96
Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res (2005) 1.80
CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol (2007) 1.77
Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease. Circulation (2015) 1.69
The LDL modification hypothesis of atherogenesis: an update. J Lipid Res (2008) 1.66
Do US Black Women Experience Stress-Related Accelerated Biological Aging?: A Novel Theory and First Population-Based Test of Black-White Differences in Telomere Length. Hum Nat (2010) 1.66
Leukocyte telomere length and carotid artery intimal medial thickness: the Framingham Heart Study. Arterioscler Thromb Vasc Biol (2008) 1.64
Biological markers of oxidative stress: Applications to cardiovascular research and practice. Redox Biol (2013) 1.63
Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev (2010) 1.58
Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm (2010) 1.49
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease. PLoS One (2016) 1.39
Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. J Nanobiotechnology (2010) 1.38
AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol (2007) 1.35
CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol (2007) 1.32
Race-Ethnicity, Poverty, Urban Stressors, and Telomere Length in a Detroit Community-based Sample. J Health Soc Behav (2015) 1.31
Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair (2008) 1.30
The role of reactive oxygen species and proinflammatory cytokines in type 1 diabetes pathogenesis. Ann N Y Acad Sci (2013) 1.30
Oxidative stress and accelerated vascular aging: implications for cigarette smoking. Front Biosci (Landmark Ed) (2009) 1.30
Association between oxidized LDL, obesity and type 2 diabetes in a population-based cohort, the Health, Aging and Body Composition Study. Diabetes Metab Res Rev (2009) 1.28
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag (2009) 1.24
Local adipose tissue renin-angiotensin system. Curr Hypertens Rep (2008) 1.23
Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res (2016) 1.20
Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol (2012) 1.20
Oxidative stress contributes to the augmented exercise pressor reflex in peripheral arterial disease patients. J Physiol (2012) 1.20
Intermittent hypoxia has organ-specific effects on oxidative stress. Am J Physiol Regul Integr Comp Physiol (2008) 1.19
Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med (2011) 1.18
Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A (2006) 1.16
Current Concepts of the Role of Oxidized LDL Receptors in Atherosclerosis. Curr Atheroscler Rep (2012) 1.16
Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease. Free Radic Biol Med (2005) 1.15
Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis (2006) 1.15
Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol (2009) 1.13
GCH1 haplotype determines vascular and plasma biopterin availability in coronary artery disease effects on vascular superoxide production and endothelial function. J Am Coll Cardiol (2008) 1.13
Ultrafine particles from diesel engines induce vascular oxidative stress via JNK activation. Free Radic Biol Med (2008) 1.11
Cigarette smoke and inflammation: role in cerebral aneurysm formation and rupture. Mediators Inflamm (2012) 1.08
The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci (2013) 1.07
Redox control of vascular smooth muscle migration. Antioxid Redox Signal (2010) 1.06
Role of mitochondrial oxidative stress in hypertension. Am J Physiol Heart Circ Physiol (2013) 1.04
Roles of IL-6-gp130 Signaling in Vascular Inflammation. Curr Cardiol Rev (2008) 1.04
Hemodynamic forces, vascular oxidative stress, and regulation of BMP-2/4 expression. Antioxid Redox Signal (2009) 1.02
Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages. Toxicol Appl Pharmacol (2009) 1.02
Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis. Antioxid Redox Signal (2009) 1.01
Oscillatory shear stress induces mitochondrial superoxide production: implication of NADPH oxidase and c-Jun NH2-terminal kinase signaling. Antioxid Redox Signal (2011) 1.01
Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med (2013) 1.01
Contribution of oxidative stress to pulmonary arterial hypertension. World J Cardiol (2010) 1.00
The role of tobacco smoke induced mitochondrial damage in vascular dysfunction and atherosclerosis. Mutat Res (2007) 1.00
NADPH oxidase has a directional response to shear stress. Am J Physiol Heart Circ Physiol (2008) 0.99
The mitochondrial paradigm for cardiovascular disease susceptibility and cellular function: a complementary concept to Mendelian genetics. Lab Invest (2011) 0.99
Effects of smoking and smoking cessation on human serum metabolite profile: results from the KORA cohort study. BMC Med (2013) 0.98
Mechanosensitive microRNAs-role in endothelial responses to shear stress and redox state. Free Radic Biol Med (2013) 0.98
Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol (2008) 0.98
Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD. Transl Res (2007) 0.98
The emerging role of cardiovascular risk factor-induced mitochondrial dysfunction in atherogenesis. J Biomed Sci (2009) 0.97
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis (2009) 0.97
Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br J Pharmacol (2010) 0.97
Total antioxidant status and 8-hydroxy-2'-deoxyguanosine levels in gingival and peripheral blood of periodontitis patients. Arch Immunol Ther Exp (Warsz) (2007) 0.97
Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol (2012) 0.96
Regional left ventricular myocardial dysfunction as a predictor of incident cardiovascular events MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol (2011) 0.96
Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol (2012) 0.95
Hydrogen peroxide regulation of endothelial exocytosis by inhibition of N-ethylmaleimide sensitive factor. J Cell Biol (2005) 0.95
Evidence for the importance of OxPAPC interaction with cysteines in regulating endothelial cell function. J Lipid Res (2012) 0.94
Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx. PLoS One (2013) 0.93
A dynamic model of calcific nodule destabilization in response to monocyte- and oxidized lipid-induced matrix metalloproteinases. Am J Physiol Cell Physiol (2011) 0.93
Rapeseed oil fortified with micronutrients reduces atherosclerosis risk factors in rats fed a high-fat diet. Lipids Health Dis (2011) 0.92
Differential Role of Leptin and Adiponectin in Cardiovascular System. Int J Endocrinol (2015) 0.92
Nrf2 and cardiovascular defense. Oxid Med Cell Longev (2013) 0.91
Phytochemical activation of Nrf2 protects human coronary artery endothelial cells against an oxidative challenge. Oxid Med Cell Longev (2012) 0.91
A pharmacological appraisal of medicinal plants with antidiabetic potential. J Pharm Bioallied Sci (2012) 0.91
The mitochondrial T16189C polymorphism is associated with coronary artery disease in Middle European populations. PLoS One (2011) 0.90
Activation-dependent stabilization of the human thromboxane receptor: role of reactive oxygen species. J Lipid Res (2009) 0.89
Thrombin inhibition by dabigatran attenuates atherosclerosis in ApoE deficient mice. Arch Med Sci (2014) 0.89
Parkinson's disease is related to an increased risk of ischemic stroke-a population-based propensity score-matched follow-up study. PLoS One (2013) 0.89
Differential carbonylation of proteins as a function of in vivo oxidative stress. J Proteome Res (2011) 0.89
Plasma total cysteine and cardiovascular risk burden: action and interaction. ScientificWorldJournal (2012) 0.88
Assessing mitochondrial redox status by flow cytometric methods: vascular response to fluid shear stress. Curr Protoc Cytom (2011) 0.87
The Interplay between ROS and Ras GTPases: Physiological and Pathological Implications. J Signal Transduct (2011) 0.86
Nox2 as a potential target of mitochondrial superoxide and its role in endothelial oxidative stress. Am J Physiol Heart Circ Physiol (2013) 0.86
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol (2009) 0.86
Nanotoxicity overview: nano-threat to susceptible populations. Int J Mol Sci (2014) 0.86
Heme oxygenase-1 induction depletes heme and attenuates pulmonary artery relaxation and guanylate cyclase activation by nitric oxide. Am J Physiol Heart Circ Physiol (2008) 0.86
Carnosic acid reduces cytokine-induced adhesion molecules expression and monocyte adhesion to endothelial cells. Eur J Nutr (2009) 0.86
Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep (2015) 0.86
Reactive oxygen species cause endothelial dysfunction in chronic flow overload. J Appl Physiol (1985) (2010) 0.86
Anti-TNF-α activity of Portulaca oleracea in vascular endothelial cells. Int J Mol Sci (2012) 0.85
Thioredoxin and thioredoxin reductase control tissue factor activity by thiol redox-dependent mechanism. J Biol Chem (2012) 0.85
Association between previously identified loci affecting telomere length and coronary heart disease (CHD) in Han Chinese population. Clin Interv Aging (2014) 0.85
MiR-146a regulates SOD2 expression in H2O2 stimulated PC12 cells. PLoS One (2013) 0.85
Nox-derived ROS are acutely activated in pressure overload pulmonary hypertension: indications for a seminal role for mitochondrial Nox4. Am J Physiol Heart Circ Physiol (2013) 0.85
Renal vasoconstriction is augmented during exercise in patients with peripheral arterial disease. Physiol Rep (2013) 0.85
Nox4 NADPH oxidase contributes to smooth muscle cell phenotypes associated with unstable atherosclerotic plaques. Redox Biol (2014) 0.84
The role of urate and xanthine oxidase in vascular oxidative stress: future directions. Ther Clin Risk Manag (2009) 0.84
CLIC1 Inhibition Attenuates Vascular Inflammation, Oxidative Stress, and Endothelial Injury. PLoS One (2016) 0.84
Lactosylceramide causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Med Sci Monit (2009) 0.83
An interaction between the interleukin-6 -174G>C gene variant and urinary protein excretion influences plasma oxidative stress in subjects with type 2 diabetes. Cardiovasc Diabetol (2004) 0.83
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet (2004) 9.35
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol (2006) 7.84
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75
Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation (2006) 5.99
A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell (2007) 5.85
Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med (2010) 5.43
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2003) 4.56
Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation (2005) 4.20
Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation (2002) 3.95
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Nox proteins in signal transduction. Free Radic Biol Med (2009) 3.47
Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem (2004) 3.37
Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res (2002) 3.32
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Measurement of reactive oxygen species in cardiovascular studies. Hypertension (2007) 3.17
Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension (2003) 3.15
Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (2006) 3.13
The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci (2003) 3.13
Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation (2005) 3.12
Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol (2002) 3.10
Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov (2011) 3.08
Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res (2012) 3.02
The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res (2006) 2.85
Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res (2009) 2.83
NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol (2009) 2.83
Clinical applications of stem cells for the heart. Circ Res (2005) 2.78
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Endothelial function: a critical determinant in atherosclerosis? Circulation (2004) 2.71
Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med (2008) 2.68
Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ (2014) 2.62
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res (2004) 2.45
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat Protoc (2009) 2.34
Modulation of vascular smooth muscle signaling by reactive oxygen species. Physiology (Bethesda) (2006) 2.24
NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol (2008) 2.22
Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail (2002) 2.18
Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation (2013) 2.11
Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem (2003) 2.09
Oxidative stress and diabetic cardiovascular complications. Free Radic Biol Med (2005) 2.05
Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol (2009) 2.01
Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol (2007) 1.97
Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res (2006) 1.89
Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.88
Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation (2002) 1.87
Increased collagen deposition and diastolic dysfunction but preserved myocardial hypertrophy after pressure overload in mice lacking PKCepsilon. Circ Res (2005) 1.86
Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res (2003) 1.86
Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation (2010) 1.85
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J (2008) 1.81
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation (2003) 1.81
Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. Circ Cardiovasc Genet (2009) 1.81
Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med (2007) 1.81
Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur Heart J (2011) 1.80
ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res (2003) 1.78
Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J (2009) 1.78
Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res (2007) 1.77
Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation (2010) 1.76
Postpartum cardiomyopathy: a cardiac emergency for gynecologists, general practitioners, internists, pulmonologists, and cardiologists. Dtsch Arztebl Int (2008) 1.75
Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation (2009) 1.73
Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J Renin Angiotensin Aldosterone Syst (2003) 1.73
Accuracy of low-dose computed tomography coronary angiography using prospective electrocardiogram-triggering: first clinical experience. Eur Heart J (2008) 1.72
The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Ther (2008) 1.72
Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res (2002) 1.71
2014 ESC/EACTS guidelines on myocardial revascularization. Rev Esp Cardiol (Engl Ed) (2015) 1.69
Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol (2010) 1.69
Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation (2004) 1.69
Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res (2002) 1.68
Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell (2011) 1.67
Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation (2013) 1.64
NAD(P)H oxidase-derived reactive oxygen species as mediators of angiotensin II signaling. Antioxid Redox Signal (2002) 1.64
Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol (2007) 1.63
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation (2003) 1.60